Grant: Engage Grants Program
University of British Columbia
$25,000.00
Research and use of high-throughput robotic screens to identify fucoidanases and sulfatases from marine environments
EF 2015-16
Résumé
Fucoidan is a polysaccharide found in seaweed that has been found, by ARC Medical Devices Inc., to be very
effective in reducing adhesion developments in the abdominal cavities of animals after surgery. The success of
this product in veterinary use has prompted a desire to develop the product for use in humans. Currently ARC
purchases the fucoidan, but the material obtained is of heterogeneous composition.
In order to move the product into the human market, they need to develop means to improve homogeneity and
purity, and to lower the average molecular weight. Two routes are possible: modifying and purifying the
commercial fucoidan, or enzymatically synthesising custom fucoidan from pure simple starting materials. The
most practical way towards both ends is to first find enzymes that can degrade fucoidan, and use these to
generate material of the desired size, then purify this lower molecular weight material. The other would be to
engineer these degradative enzymes into synthetic enzymes and use these to assemble fucoidan of the desired
properties. This is however challenging as no fucoidanases have ever been isolated and cloned to our
knowledge, but such enzymes must exist. Several approaches to this are possible. Our approach is to screen
both libraries of marine bacteria and fragments of genes from marine sources, some of which may well use
seaweed as a food source, to look for fucoidanase activity. We shall then identify the responsible genes and
from them produce the enzymes to test whether they can carry out the desired task. Successful completion of
the project will lead to a process to produce a novel, first in class medical device for the reduction of
post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in
Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital
re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and
taxpayers; and create scientific, manufacturing and sales jobs within Canada, and export of a high margin
product.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
486082-2015
Name nom
Withers, Stephen
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5406
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
1
Nb partie
1
Application title
Research and use of high-throughput robotic screens to identify fucoidanases and sulfatases from marine environments
Keyword
NSERC
Application summary
Fucoidan is a polysaccharide found in seaweed that has been found, by ARC Medical Devices Inc., to be very
effective in reducing adhesion developments in the abdominal cavities of animals after surgery. The success of
this product in veterinary use has prompted a desire to develop the product for use in humans. Currently ARC
purchases the fucoidan, but the material obtained is of heterogeneous composition.
In order to move the product into the human market, they need to develop means to improve homogeneity and
purity, and to lower the average molecular weight. Two routes are possible: modifying and purifying the
commercial fucoidan, or enzymatically synthesising custom fucoidan from pure simple starting materials. The
most practical way towards both ends is to first find enzymes that can degrade fucoidan, and use these to
generate material of the desired size, then purify this lower molecular weight material. The other would be to
engineer these degradative enzymes into synthetic enzymes and use these to assemble fucoidan of the desired
properties. This is however challenging as no fucoidanases have ever been isolated and cloned to our
knowledge, but such enzymes must exist. Several approaches to this are possible. Our approach is to screen
both libraries of marine bacteria and fragments of genes from marine sources, some of which may well use
seaweed as a food source, to look for fucoidanase activity. We shall then identify the responsible genes and
from them produce the enzymes to test whether they can carry out the desired task. Successful completion of
the project will lead to a process to produce a novel, first in class medical device for the reduction of
post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in
Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital
re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and
taxpayers; and create scientific, manufacturing and sales jobs within Canada, and export of a high margin
product.